The Link Between the Mirena IUD and PTC

Mirena Update April 2017: the Mirena birth control legal team at Jones Ward PLC argued this month in favor of consolidating more than 100 pseudotumor cerebri cases as part of a mass tort proceeding. A panel of federal judges agreed, and the cases are now proceeding in U.S. District Court for the Southern District of New York. The cases are now part of a proceeding called Multidistrict Litigation, or MDL for short. Judge Paul Engelmayer will over see the proceeding. The injury lawyers at Jones Ward believe this will be beneficial for injured women as it will make the litigation more efficient and allow plaintiffs to combine forces in their fight against Bayer. Jones Ward represents more women with Mirena injury lawsuits than any other law firm in the nation. The formal name of the proceeding is now In RE: Mirena IUS Levonorgestrel-Related Products Liability Litigation (No. II) — MDL No. 2767.

The Mirena IUD lawyers at Jones Ward have filed dozens of Mirena IUD lawsuits on behalf of victims who now suffer from the debilitating pseudotumor cerebri (PTC) condition.

The PTC condition arises when cerebrospinal fluid in the brain accumulates and creates pressure in the skull, leading to swollen optic nerves. If not diagnosed and treated properly, permanent damage, including blindness, can result.

The Mirena Hormone

The Mirena IUD releases 20 micrograms of the synthetic hormone levonorgestrel per day. Long-term exposure to levonorgestrel has been linked to the development of PTC.

Levonorgestrel is a second-generation synthetic hormone. It’s natural counterpart, progesterone, has not been linked to PTC, and has actually been shown to help the brain heal after traumatic brain injuries. Levonorgestrel, on the other hand, has been shown to do the opposite.

PTC Symptoms From Exposure to Mirena IUD Levonorgestrel

The victims of Mirena that develop PTC typically report the following symptoms:

• Severe, migraine-like headaches
• “Whoosing” sounds (clinically known as tinnitus)
• Blurred vision
• Double vision (diplopia)
• Changes in migraine frequency, severity, or duration

The Case Against the Mirena IUD Manufacturer

The Mirena label has no information alerting physicians and patients that its product may lead to an increased risk of developing the condition. Thus, for many women, even if correctly diagnosed with PTC, which often takes months of testing, their doctors may not know that Mirena is related to the diagnosis and more importantly, that it should be removed immediately upon diagnosis.

PTC is reported to be relatively rare, although there is a higher risk of developing the condition among overweight women of child-bearing age. Yet the Mirena IUD has also been linked to sudden and increased weight gain, highlighting the importance of warning women who are already at a higher risk of developing the condition.

Women who have PTC and levonorgestrel-releasing implants (like Mirena) should have their implants removed. Yet again, Bayer fails to notify doctors of this fact.
The dangerous drug attorneys at Jones Ward are litigating cases involving women who develop PTC while using the Mirena IUD. For more information, contact the Mirena attorneys at Jones Ward PLC by emailing Christina Natale at or click here.